日本血液净化治疗临床实践指南
该指南由日本血液净化治疗学会制定,汇集急诊医学、血液学、风湿病学、呼吸、心血管、消化、神经、肾脏和皮肤科等熟悉血液净化治疗的专家,覆盖86种疾病。鉴于多数适应症为罕见难治性疾病、难以开展大规模随机对照试验,且日本主流采用膜分离法(如双重滤过血浆置换、选择性血浆交换)及吸附型设备(如多粘菌素B固定化内毒素吸附柱),与美国ASFA指南的离心分离法及疾病背景不同,直接套用ASFA指南在日本存在诸多问题。指南以工作表形式呈现,便于医师、临床工程师、护士、营养师等床旁理解使用,旨在总结日本血液净化治疗并推广至全球。随着诊疗技术不断进步,指南需每隔数年修订,日本血液净化治疗学会登记系统与指南密不可分。
要点
- 指南由日本血液净化治疗学会制定,涵盖86种疾病,以工作表形式便于床旁快速查阅。
- 日本主流采用膜分离法(如DFPP、选择性血浆交换)及吸附型设备(如多粘菌素B固定化内毒素吸附柱),与美国ASFA指南的离心分离法不同。
- 多数适应症为罕见难治性疾病,难以开展大规模随机对照试验获取高质量证据。
- 直接套用ASFA指南在日本临床实践会产生各种问题,因目标疾病及其背景与日本不同。
- 日本血液净化治疗学会登记系统与指南不可分割,共同保障治疗质量;指南需每隔数年修订。
适用人群与场景
- 适用于日本血液净化治疗的临床实践,覆盖86种疾病,涉及急诊医学、血液学、胶原病/风湿病学、呼吸医学、心血管医学、消化病学、神经病学、肾脏病学和皮肤病学等专科。
- 血液净化治疗涉及医师、临床工程师、护士、营养师等多类专业人员的协作。
研究设计与关键结果
- 指南由日本血液净化治疗学会组织熟悉血液净化治疗的多个专科专家共同制定,覆盖86种疾病,以工作表形式呈现以便床旁理解。
- 日本血液净化治疗的特点包括中空纤维设备(如双重滤过血浆置换(DFPP)、选择性血浆交换)和吸附型设备(如多粘菌素B固定化内毒素吸附柱)的治疗方法开发。
- 美国主要使用离心分离法进行血液净化,而日本主流为膜分离法,目标疾病及其背景也与日本不同,直接采用ASFA指南在日本实践会产生各种问题。
证据类型、等级与局限
- 证据类型:临床实践指南;由日本血液净化治疗学会制定,汇集多学科专家。
- 指南指出多数适应症为罕见难治性疾病,难以开展大规模随机对照试验以获取高质量证据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在日本临床实践中,应参考日本血液净化治疗学会指南而非直接套用ASFA指南,因分离方法(膜分离法 vs 离心分离法)和目标疾病背景存在差异。
- 床旁可使用该指南的工作表形式快速查阅86种疾病的血液净化治疗推荐。
- 日本血液净化治疗学会登记系统与指南共同用于保障治疗质量,指南需每隔数年修订。
指南或共识出处
- 指南名称:日本血液净化治疗学会临床实践指南(The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis);发布机构:日本血液净化治疗学会(The Japanese Society for Apheresis);发表于《Therapeutic Apheresis and Dialysis》。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Most of the diseases for which apheresis therapy is indicated are intractable and rare, and each patient has a different background and treatment course prior to apheresis therapy initiation. Therefore, it is difficult to conduct large-scale randomized controlled trials to secure high-quality evidence. Under such circumstances, the American Society for Apheresis (ASFA) issued its guidelines in 2007, which were repeatedly revised until the latest edition in 2019. The ASFA guidelines are comprehensive. However, in the United States, a centrifugal separation method is mainly used for apheresis, whereas the mainstream procedure in Japan is the membrane separation method. The target diseases and their backgrounds are different from those in Japan. Due to these differences, the direct adoption of the ASFA guidelines in Japanese practice creates various problems. One of the features of apheresis in Japan is the development of treatment methods using hollow-fiber devices such as double filtration plasmapheresis (DFPP) and selective plasma exchange and adsorption-type devices such as polymyxin B-immobilized endotoxin adsorption columns. Specialists in emergency medicine, hematology, collagen diseases/rheumatology, respiratory medicine, cardiovascular medicine, gastroenterology, neurology, nephrology, and dermatology who are familiar with apheresis therapy gathered for this guideline, which covers 86 diseases. In addition, since apheresis therapy involves not only physicians but also clinical engineers, nurses, dieticians, and many other medical professionals, this guideline was prepared in the form of a worksheet so that it can be easily understood at the bedside. Moreover, to the clinical purposes, this guideline is designed to summarize apheresis therapy in Japan and to disseminate and further develop Japanese apheresis technology to the world. As diagnostic and therapeutic techniques are constantly advancing, the guidelines need to be revised every few years. In order to ensure the high quality of apheresis therapy in Japan, both the Japanese Society for Apheresis Registry and the guidelines will be inseparable.
参考来源
- Abe T, Matsuo H, Abe R, et al. The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis. Ther Apher Dial. 2021. PMID: 34877777. doi:10.1111/1744-9987.13749
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。